CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
CPXX was delisted on the 11th of July, 2016.
119 hedge funds and large institutions have $944M invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2016 Q2 according to their latest regulatory filings, with 86 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 24 closing their positions.
344% more call options, than puts
Call options by funds: $95M | Put options by funds: $21.4M
342% more capital invested
Capital invested by funds: $214M → $944M (+$731M)
258% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 24
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
105% more funds holding
Funds holding: 58 → 119 (+61)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$45M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$32.3M |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$22.6M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$19.9M |
| 5 |
GCL
Glazer Capital LLC
New York
|
+$19.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$16M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.6M |
| 3 |
Millennium Management
New York
|
-$12.6M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.38M |
CPXX Hedge Fund Activity: Q2 2016 in Review
119 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q2 2016, worth a combined $944M — up 342% from $214M a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new CPXX positions and 24 closed out — a net gain of 62 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $45M. The largest seller was Visium Asset Management, exiting entirely with an estimated $16M sold.
- 119 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q2 2016, up from 58 in Q1 2016.
- Funds reported $944M of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q2 2016, up 342% quarter-over-quarter.
- 86 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q2 2016 and 24 closed out, a net change of +62 holders.
- The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK buyer in Q2 2016 was Alpine Associates Management, an estimated $45M added.
- The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK seller in Q2 2016 was Visium Asset Management, an estimated $16M sold.
Based on aggregated 13F filings for Q2 2016.